Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review

References

• Kohn N. The significance of calcium pyrophosphate crystals in the synovial fluid of arthritic patients: the ‘pseudogout syndrome’. II Identification of crystals. Ann Intern Med. 1962;56(56):738–745. doi:10.7326/0003-4819-56-5-738
   PubMedGoogle Scholar
• Salaffi F, De Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. Clin Exp Rheumatol. 2005;23(6):819–828.
   PubMed Web of Science ®Google Scholar
• Musacchio E, Ramonda R, Perissinotto E. The impact of knee and hip chondrocalcinosis on disability in older people: the ProVA study from northeastern Italy. Ann Rheum Dis. 2011;70(11):1937–1943. doi:10.1136/ard.2011.150508
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563–570. doi:10.1136/ard.2010.139105
   PubMed Web of Science ®Google Scholar
• Tedeschi S. Identifying potential classification criteria for calcium pyrophosphate deposition disease: item generation and item reduction. Arthritis Care Res. 2021;10:1002.
   Google Scholar
• Ea HK, Lioté F. Diagnosis and clinical manifestations of calcium pyrophosphate and basic calcium phosphate crystal deposition diseases. Rheum Dis Clin North Am. 2014;40(2):207–229. doi:10.1016/j.rdc.2014.01.011
   PubMed Web of Science ®Google Scholar
• Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology. 2009;48(7):711–715. doi:10.1093/rheumatology/kep081
   PubMed Web of Science ®Google Scholar
• Macmullan P, McCarthy G. Treatment and management of pseudogout: insights for the clinician. Ther Adv Musculoskelet Dis. 2012;4(2):121–131. doi:10.1177/1759720X11432559
   PubMedGoogle Scholar
• Abhishek A, Doherty S, Maciewicz R, et al. Chondrocalcinosis is common in the absence of knee involvement. Arthritis Res Ther. 2012;14(5):R205. doi:10.1186/ar4043
   PubMed Web of Science ®Google Scholar
• Dieppe PA, Doherty M, Macfarlane DG, et al. Apatite associated destructive arthritis. Br J Rheumatol. 1984;23(2):84–91. doi:10.1093/rheumatology/23.2.84
   PubMedGoogle Scholar
• Cipolletta E, Filippucci E, Abhishek A, et al. In patients with acute mono-oligoarthritis, a targeted ultrasound scanning protocol shows great accuracy for the diagnosis of gout and CPPD. Rheumatology. 2022. doi:10.1093/rheumatology/keac479
   Google Scholar
• Felson DT, Anderson JJ, Naimark A, et al. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham study. J Rheumatol. 1989;16(9):1241–1245.
   PubMed Web of Science ®Google Scholar
• Iqbal SM, Qadir S, Aslam HM, et al. Updated treatment for calcium pyrophosphate deposition disease: an insight. Cureus. 2019;11(1):e3840. doi:10.7759/cureus.3840
   PubMed Web of Science ®Google Scholar
• Ivory D, Velázquez CR. The forgotten crystal arthritis: calcium pyrophosphate deposition. Mo Med. 2012;109(1):64–68.
   PubMedGoogle Scholar
• McCarthy G. Primer on the Rheumatic Diseases. 13th ed. Berlin: Springer; 2008.
   Google Scholar
• Masuda I, Ishikawa K. Clinical features of pseudogout attack. A survey of 50 cases. Clin Orthop Relat Res. 1988;229:173–181.
   Google Scholar
• Rosales-Alexander JL, Balsalobre Aznar J, Magro-Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatol. 2014;6:39–47. doi:10.2147/OARRR.S39039
   PubMedGoogle Scholar
• Rosenthal AK, Ryan LM, Campion EW. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575–2584. doi:10.1056/NEJMra1511117
   PubMed Web of Science ®Google Scholar
• Oza P, Reginato AM, Alexander B, Franciscus C, Turvey C. Calcium-containing crystal-associated arthropathies in the elderly. Fed Pract. 2016;33(4):14–20. doi:10.1097/MLR.0000000000000108
   PubMedGoogle Scholar
• Resnick D, Williams G, Weisman MH, et al. Rheumatoid arthritis and pseudo-rheumatoid arthritis in calcium pyrophosphate dihydrate crystal deposition disease. Radiology. 1981;140(3):615–621. doi:10.1148/radiology.140.3.6269144
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa JM, Rodriguez-Rodriguez M, Hurtado-Hernandez Z, et al. Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective follow up study of predictive factors for this condition in patients presenting with polymyalgia symptoms. Arthritis Rheum. 2005;53(6):931–938. doi:10.1002/art.21585
   PubMedGoogle Scholar
• Richards AJ, Hamilton EB. Destructive arthropathy in chondrocalcinosis articularis. Ann Rheum Dis. 1974;33(3):196–203. doi:10.1136/ard.33.3.196
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Iwasaki H, Ohjimi Y, et al. Tumoral calcium pyrophosphate dihydrate crystal deposition disease. A clinicopathologic analysis of five cases. Pathol Res Pract. 2001;197(7):499–506. doi:10.1078/0344-0338-00118
   PubMed Web of Science ®Google Scholar
• Ishida T, Dorfman HD, Bullough PG. Tophaceous pseudogout (tumoral calcium pyrophosphate dihydrate crystal deposition disease). Hum Pathol. 1995;26(6):587–593. doi:10.1016/0046-8177(95)90161-2
   PubMed Web of Science ®Google Scholar
• Nakase T, Takeuchi E, Sugamoto K, et al. Involvement of multinucleated giant cells synthesizing cathepsin K in calcified tendinitis of the rotator cuff tendons. Rheumatology. 2000;39(10):1074–1077. doi:10.1093/rheumatology/39.10.1074
   PubMed Web of Science ®Google Scholar
• Rho YH, Zhu Y, Zhang Y, et al. Risk factors for pseudogout in the general population. Rheumatology. 2012;51(11):2070–2074. doi:10.1093/rheumatology/kes204
   PubMed Web of Science ®Google Scholar
• Doherty M. New insights into the epidemiology of gout. Rheumatology. 2009;48(Suppl 2):ii2–ii8. doi:10.1093/rheumatology/kep086
   PubMed Web of Science ®Google Scholar
• Bernardeau C, Bucki B, Lioté F. Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann Rheum Dis. 2001;60(5):518–520. doi:10.1136/ard.60.5.518
   PubMed Web of Science ®Google Scholar
• Elbeialy AA, Bauomi AM, Elnaggar BM, et al. Middle East pain syndrome is a pollution-induced new disease mimicking rheumatoid arthritis. Sci Rep. 2021;11(1):22263. doi:10.1038/s41598-021-01698-1
   PubMed Web of Science ®Google Scholar
• Chotard E, Blanchard A, Ostertag A, et al. Calcium pyrophosphate crystal deposition in a cohort of 57 patients with Gitelman syndrome. Rheumatology. 2022;61(6):2494–2503. doi:10.1093/rheumatology/keab578
   PubMed Web of Science ®Google Scholar
• Adamson TC, Resnik CS, Guerra J, et al. Hand and wrist arthropathies of hemochromatosis and calcium pyrophosphate deposition disease: distinct radiographic features. Radiology. 1983;147(2):377–381. doi:10.1148/radiology.147.2.6300958
   PubMed Web of Science ®Google Scholar
• Doherty M, Watt I, Dieppe PA. Localised chondrocalcinosis in post-meniscectomy knees. Lancet. 1982;1(8283):1207–1210. doi:10.1016/S0140-6736(82)92336-4
   PubMed Web of Science ®Google Scholar
• Tedeschi SK, Pascart T, Latourte A, et al. Identifying potential classification criteria for calcium pyrophosphate deposition disease: item generation and item reduction. Arthritis Care Res. 2022;74(10):1649–1658. doi:10.1002/acr.24619
   Web of Science ®Google Scholar
• Tedeschi SK. Issues in CPPD nomenclature and classification. Curr Rheumatol Rep. 2019;21(9):49. doi:10.1007/s11926-019-0847-4
   PubMed Web of Science ®Google Scholar
• Pascual E. Synovial Fluid Analysis and the Evaluation of Patients with Arthritis. Mandell BF, editor. Springer; 2022.
   Google Scholar
• Schumacher HR, Sieck MS, Rothfuss S, et al. Reproducibility of synovial fluid analyses. A study among four laboratories. Arthritis Rheum. 1986;29(6):770–774. doi:10.1002/art.1780290610
   PubMedGoogle Scholar
• Berendsen D, Neogi T, Taylor WJ, et al. Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training. Clin Rheumatol. 2017;36(3):641–647. doi:10.1007/s10067-016-3461-0
   PubMed Web of Science ®Google Scholar
• Miksanek J, Rosenthal AK. Imaging of calcium pyrophosphate deposition disease. Curr Rheumatol Rep. 2015;17(3):20. doi:10.1007/s11926-015-0496-1
   PubMed Web of Science ®Google Scholar
• Resnick D, Niwayama G, Goergen TG, et al. Clinical, radiographic and pathologic abnormalities in calcium pyrophosphate dihydrate deposition disease (CPPD): pseudogout. Radiology. 1977;122(1):1–15. doi:10.1148/122.1.1
   PubMed Web of Science ®Google Scholar
• Ryan LM. Calcium Pyrophosphate Crystal Deposition Disease, Pseudogout and Articular Chondrocalcinosis. McCarty DJ, editor. Philadelphia: Lea and Febiger; 1997.
   Google Scholar
• Filippou G, Scirè CA, Adinolfi A, et al. Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints—an international multiobserver study by the OMERACT calcium pyrophosphate deposition disease ultrasound subtask force. Ann Rheum Dis. 2018;77(8):1194–1199. doi:10.1136/annrheumdis-2017-212542
   PubMed Web of Science ®Google Scholar
• Grassi W, Okano T, Filippucci E. Use of ultrasound for diagnosis and monitoring of outcomes in crystal arthropathies. Curr Opin Rheumatol. 2015;27(2):147–155. doi:10.1097/BOR.0000000000000142
   PubMed Web of Science ®Google Scholar
• Filippou G, Scanu A, Adinolfi A, et al. Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study. Ann Rheum Dis. 2021;80(2):261–267. doi:10.1136/annrheumdis-2020-217998
   PubMed Web of Science ®Google Scholar
• Filippou G, Scirè CA, Damjanov N, et al. Definition and reliability assessment of elementary ultrasonographic findings in calcium pyrophosphate deposition disease: a study by the OMERACT calcium pyrophosphate deposition disease ultrasound subtask force. J Rheumatol. 2017;44(11):1744–1749. doi:10.3899/jrheum.161057
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Di Geso L, Salaffi F, et al. Ultrasound detection of cartilage calcification at knee level in calcium pyrophosphate deposition disease. Arthritis Care Res. 2014;66(1):69–73. doi:10.1002/acr.22190
   Web of Science ®Google Scholar
• Forien M, Combier A, Gardette A, et al. Comparison of ultrasonography and radiography of the wrist for diagnosis of calcium pyrophosphate deposition. Joint Bone Spine. 2018;85(5):615–618. doi:10.1016/j.jbspin.2017.09.006
   PubMed Web of Science ®Google Scholar
• Becce F. Diagnosis of calcium pyrophosphate deposition by imaging - current state and challenges remaining. Osteoarthr Cartil. 2019;27(4):545–546. doi:10.1016/j.joca.2019.01.015
   PubMed Web of Science ®Google Scholar
• McCarthy GM, Dunne A. Calcium crystal deposition diseases - beyond gout. Nat Rev Rheumatol. 2018;14(10):592–602. doi:10.1038/s41584-018-0078-5
   PubMed Web of Science ®Google Scholar
• Lee GS, Kim RS, Park HK, et al. Crowned dens syndrome: a case report and review of the literature. Korean J Spine. 2014;11(1):15–17. doi:10.14245/kjs.2014.11.1.15
   PubMedGoogle Scholar
• Pascart T, Falgayrac G, Norberciak L, et al. Dual-energy computed-tomography-based discrimination between basic calcium phosphate and calcium pyrophosphate crystal deposition in vivo. Ther Adv Musculoskelet Dis. 2020;12:1759720x20936060. doi:10.1177/1759720X20936060
   Web of Science ®Google Scholar
• Suan JC, Chhem RK, Gati JS, et al. 4 T MRI of chondrocalcinosis in combination with three-dimensional CT, radiography, and arthroscopy: a report of three cases. Skeletal Radiol. 2005;34(11):714–721. doi:10.1007/s00256-005-0930-y
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70(4):571–575. doi:10.1136/ard.2010.139360
   PubMed Web of Science ®Google Scholar
• Parperis K, Papachristodoulou E, Kakoullis L, et al. Management of calcium pyrophosphate crystal deposition disease: a systematic review. Semin Arthritis Rheum. 2021;51(1):84–94. doi:10.1016/j.semarthrit.2020.10.005
   PubMed Web of Science ®Google Scholar
• Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13(4):804–805.
   PubMed Web of Science ®Google Scholar
• O’Duffy JD. Pseudogout syndrome in hospital patients. JAMA. 1973;226(1):42–44. doi:10.1001/jama.1973.03230010020004
   PubMed Web of Science ®Google Scholar
• Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol. 1994;21(4):696–699.
   PubMed Web of Science ®Google Scholar
• Cipolletta E, Di Matteo A, Scanu A, et al. Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review. Clin Exp Rheumatol. 2020;38(5):1001–1007.
   PubMed Web of Science ®Google Scholar
• Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014;16(5):458. doi:10.1186/s13075-014-0458-4
   PubMed Web of Science ®Google Scholar
• Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18(5):234–236. doi:10.1097/RHU.0b013e3182611471
   PubMed Web of Science ®Google Scholar
• Latourte A, Ea H-K, Frazier A, et al. Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. Ann Rheum Dis. 2020;79(8):1126–1128. doi:10.1136/annrheumdis-2020-217188
   PubMed Web of Science ®Google Scholar
• Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997;23(5):327–331.
   PubMedGoogle Scholar